Literature DB >> 12010778

Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts.

Hideo Inoue1, Makiko Takamori, Yoshihito Shimoyama, Hideaki Ishibashi, Seizo Yamamoto, Yasuko Koshihara.   

Abstract

1. We examined the effects of endogenous prostaglandin E(2) (PGE(2)) on the production of interleukin-6 (IL-6), macrophage colony stimulating factor (M-CSF), and vascular endothelial growth factor (VEGF) by interleukin-1beta (IL-1beta)-stimulated human synovial fibroblasts. 2. NS-398 (1 microM), a cyclo-oxygenase-2 (COX-2) inhibitor, inhibited IL-6 and VEGF production (35+/-4% and 26+/-2%, respectively) but enhanced M-CSF production (38+/-4%) by IL-1beta (1 ng ml(-1)) in synovial fibroblasts isolated from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Exogenous PGE(2) completely abolished the effects of NS-398 on the production of each mediator by OA fibroblasts stimulated with IL-1beta. 3. 8-Bromo cyclic AMP and dibutyryl cyclic AMP, cyclic AMP analogues, mimicked the effects of PGE(2) on IL-6, M-CSF, and VEGF production by OA fibroblasts. 4. The EP(2) selective receptor agonist ONO-AE1-259 (2 nM) and the EP(4) selective receptor agonist ONO-AE1-329 (2 or 20 nM), but not the EP(1) selective receptor agonist ONO-DI-004 (1 microM) and the EP(3) selective receptor agonist ONO-AE-248 (1 microM), replaced the effects of PGE(2) on IL-6, M-CSF, and VEGF production by OA and RA fibroblasts stimulated with IL-1beta in the presence of NS-398. 5. Both OA and RA fibroblasts expressed mRNA encoding EP(2) and EP(4) but not EP(1) receptors. In addition, up-regulation of EP(2) and EP(4) receptor mRNAs was observed at 3 h after IL-1beta treatment. 6. These results suggest that endogenous PGE(2) regulates the production of IL-6, M-CSF, and VEGF by IL-1beta-stimulated human synovial fibroblasts through the activation of EP(2) and EP(4) receptors with increase in cyclic AMP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010778      PMCID: PMC1573344          DOI: 10.1038/sj.bjp.0704705

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  Prostaglandins in the rheumatic diseases.

Authors:  D R Robinson; M B McGuire; L Levine
Journal:  Ann N Y Acad Sci       Date:  1975-06-13       Impact factor: 5.691

2.  Proliferation of a subpopulation of human peripheral blood monocytes in the presence of colony stimulating factors may contribute to the inflammatory process in diseases such as rheumatoid arthritis.

Authors:  S T Moss; J A Hamilton
Journal:  Immunobiology       Date:  2000-05       Impact factor: 3.144

3.  Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis.

Authors:  P A Guerne; B L Zuraw; J H Vaughan; D A Carson; M Lotz
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

4.  Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells.

Authors:  J M Dayer; B de Rochemonteix; B Burrus; S Demczuk; C A Dinarello
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

5.  Release of GM-CSF and G-CSF by human arterial and venous smooth muscle cells: differential regulation by COX-2.

Authors:  S J Stanford; J R Pepper; J A Mitchell
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

6.  An investigation of cell proliferation and soluble mediators induced by interleukin 1beta in human synovial fibroblasts: comparative response in osteoarthritis and rheumatoid arthritis.

Authors:  H Inoue; M Takamori; N Nagata; T Nishikawa; H Oda; S Yamamoto; Y Koshihara
Journal:  Inflamm Res       Date:  2001-02       Impact factor: 4.575

7.  Stimulation of human synovial fibroblast DNA synthesis by recombinant human cytokines.

Authors:  D M Butler; D S Piccoli; P H Hart; J A Hamilton
Journal:  J Rheumatol       Date:  1988-10       Impact factor: 4.666

8.  Involvement of prostaglandin E(2) in interleukin-1alpha-induced parathyroid hormone-related peptide production in synovial fibroblasts of patients with rheumatoid arthritis.

Authors:  T Yoshida; H Sakamoto; T Horiuchi; S Yamamoto; A Suematsu; H Oda; Y Koshihara
Journal:  J Clin Endocrinol Metab       Date:  2001-07       Impact factor: 5.958

Review 9.  Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.

Authors:  A Ward; S P Clissold
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

10.  Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression.

Authors:  S L Kunkel; M Spengler; M A May; R Spengler; J Larrick; D Remick
Journal:  J Biol Chem       Date:  1988-04-15       Impact factor: 5.157

View more
  42 in total

1.  Prostaglandin E2 induces interleukin-6 expression in human chondrocytes via cAMP/protein kinase A- and phosphatidylinositol 3-kinase-dependent NF-kappaB activation.

Authors:  Pu Wang; Fei Zhu; Konstantinos Konstantopoulos
Journal:  Am J Physiol Cell Physiol       Date:  2010-03-24       Impact factor: 4.249

2.  Prostaglandin E2 stimulates the production of vascular endothelial growth factor through the E-prostanoid-2 receptor in cultured human lung fibroblasts.

Authors:  Masanori Nakanishi; Tadashi Sato; Yingji Li; Amy J Nelson; Maha Farid; Joel Michalski; Nobuhiro Kanaji; Xingqi Wang; Hesham Basma; Amol Patil; Jadvinder Goraya; Xiangde Liu; Shinsaku Togo; Myron L Toews; Olaf Holz; Kai-Christian Muller; Helgo Magnussen; Stephen I Rennard
Journal:  Am J Respir Cell Mol Biol       Date:  2012-02       Impact factor: 6.914

3.  Joint tissues amplify inflammation and alter their invasive behavior via leukotriene B4 in experimental inflammatory arthritis.

Authors:  Mei Chen; Bing K Lam; Andrew D Luster; Simona Zarini; Robert C Murphy; Angela M Bair; Roy J Soberman; David M Lee
Journal:  J Immunol       Date:  2010-09-27       Impact factor: 5.422

4.  The role of PGE2 receptor EP4 in pathologic ocular angiogenesis.

Authors:  Susan E Yanni; Joshua M Barnett; Monika L Clark; John S Penn
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-03       Impact factor: 4.799

5.  Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage.

Authors:  Aniruddha C Amrite; Surya P Ayalasomayajula; Narayan P S Cheruvu; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-03       Impact factor: 4.799

6.  Human retinal endothelial cells and astrocytes cultured on 3-D scaffolds for ocular drug discovery and development.

Authors:  Kay D Beharry; Charles L Cai; Gloria B Valencia; Douglas Lazzaro; Arwin M Valencia; Fabrizio Salomone; Jacob V Aranda
Journal:  Prostaglandins Other Lipid Mediat       Date:  2017-09-18       Impact factor: 3.072

7.  COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters.

Authors:  Giuseppe Perrone; Daniele Santini; Mariagiovanna Zagami; Bruno Vincenzi; Alfio Verzì; Sergio Morini; Domenico Borzomati; Roberto Coppola; Armando Antinori; Paolo Magistrelli; Giuseppe Tonini; Carla Rabitti
Journal:  Virchows Arch       Date:  2006-08-12       Impact factor: 4.064

8.  Role of prostaglandin E receptor subtypes EP2 and EP4 in autocrine and paracrine functions of vascular endothelial growth factor in the inner ear.

Authors:  Ryusuke Hori; Takayuki Nakagawa; Norio Yamamoto; Kiyomi Hamaguchi; Juichi Ito
Journal:  BMC Neurosci       Date:  2010-03-11       Impact factor: 3.288

9.  COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables.

Authors:  G Perrone; D Santini; A Verzì; B Vincenzi; D Borzomati; F Vecchio; R Coppola; A Antinori; P Magistrelli; G Tonini; C Rabitti
Journal:  J Clin Pathol       Date:  2006-02-17       Impact factor: 3.411

Review 10.  Immunopathogenesis of osteoarthritis.

Authors:  Abdul Haseeb; Tariq M Haqqi
Journal:  Clin Immunol       Date:  2013-01-06       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.